Is Teva Pharmaceutical Industries (TEVA) A Good Stock To Buy Now?

Is TEVA a bully banal to buy? We came crossed a bullish thesis connected Teva Pharmaceutical Industries Limited connected Kontra Investments’s Substack by Kontra. In this article, we volition summarize the bulls’ thesis connected TEVA. Teva Pharmaceutical Industries Limited's stock was trading astatine $31.52 arsenic of March 10th. TEVA’s trailing and guardant P/E were 26.03 and 11.60 respectively according to Yahoo Finance.

Teva Pharmaceutical Industries (TEVA) has entered a caller signifier of maturation arsenic the institution continues executing its “Pivot to Growth” strategy, transforming from a accepted generics shaper into a higher-margin innovative biopharmaceutical company. Following its Q4 and full-year 2025 results, Teva reported revenues of $17.3 billion, representing 5% year-over-year maturation and marking the 3rd consecutive twelvemonth of gross expansion.

The company’s maturation illustration is progressively driven by its innovative portfolio, highlighted by its 3 halfway branded medicines—Austedo, Ajovy, and Uzedy—which unneurotic surpassed $1 cardinal successful combined quarterly gross for the archetypal clip successful the company’s history. Austedo remains the superior maturation engine, generating $2.26 cardinal successful 2025 income (+34%), supported by beardown adoption of its once-daily XR formulation.

Ajovy delivered $673 cardinal successful planetary gross (+30%), while Uzedy, a rapidly expanding long-acting injectable therapy, grew 63% to $191 million. These innovative medicines present play a cardinal relation successful Teva’s strategy arsenic the institution continues to stabilize its planetary generics franchise, which generated astir $9.4 cardinal successful revenue.

Financially, Teva delivered beardown results crossed cardinal metrics successful 2025, including adjusted EBITDA of $5.3 cardinal (+12%), non-GAAP EPS of $2.93 (+19%), and escaped currency travel of $2.4 billion. The institution besides made meaningful advancement connected equilibrium expanse improvement, reducing nett indebtedness to $13.3 cardinal and lowering its nett debt-to-EBITDA ratio to 2.5x arsenic it targets 2.0x by 2027. Operational improvements are supported by the Teva Transformation program, which aims to make $700 cardinal successful outgo savings by 2027, with astir 20% already achieved.

Looking ahead, Teva expects 2026 to beryllium a modulation twelvemonth arsenic it absorbs a $1.1 cardinal headwind from generic Revlimid erosion, guiding revenues to $16.4–$16.8 cardinal portion maintaining beardown profitability and escaped currency flow.

Despite this near-term pressure, the company’s late-stage pipeline—estimated astatine much than $10 cardinal successful highest income potential—along with continued enlargement of its innovative portfolio positions Teva for sustained mid-single-digit maturation done the extremity of the decade. As leverage declines and escaped currency travel strengthens, investors progressively presumption Teva arsenic a biopharma turnaround with meaningful upside imaginable arsenic the marketplace begins to admit the worth of its evolving concern mix.